source
- Tessera Therapeutics reports infusion gene edit corrects 85% of blood cells in sickle cell studyTessera Therapeutics announced new data from its in-vivo gene editing program targeting sickle cell disease. The experimental therapy is given as a simple infusion, avoiding the complex cell engin…
- Merck KGaA sees client stockpiling of lab equipment amid Iran war, lifts guidanceMerck KGaA's CFO Helene von Roeder said the company is observing a rise in demand for its laboratory equipment as customers increase inventories in response to the ongoing war in Iran. The heighte…